By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

DiagnoCure Inc. 

2050 Boulevard, Rene-Levesque Ouest, 6th Floor

Sainte-Foy  Quebec  G1V 2K8  Canada
Phone: 418-527-6100 Fax: 418-527-0240


SEARCH JOBS


Industry
Biotechnology

Segment
Pharmaceuticals

Collaborations

Gen-Probe Incorporated (Acquired by Hologic)  In November 2003, Gen-Probe signed a license and collaboration agreement with DiagnoCure under which the companies are developing, and Gen-Probe will market, an innovative urine test to detect a new, highly specific genetic marker for prostate cancer called PCA3.





Company News
DiagnoCure (CUR) Reports Recommendations From Two Independent Proxy Advisory Firms Favorable To The PCA3 Asset Sale And To The Reduction Of The Stated Capital 2/2/2016 6:25:46 AM
DiagnoCure (CUR) Announces Fourth Quarter 2015 And Year-End Results As Well As Proxy Circular Filing And Business Initiatives Following The Execution Of An Asset Purchase Agreement To Sell All Its Assets Relating To PCA3 1/22/2016 6:31:22 AM
DiagnoCure (CUR) Announces The Execution of an Asset Purchase Agreement With Hologic (HOLX) 12/28/2015 6:52:49 AM
DiagnoCure (CUR) Announces Third Quarter 2015 Results 9/11/2015 7:20:22 AM
DiagnoCure (CUR) Announces Second Quarter 2015 Results And Restructures Its Board Of Directors 6/12/2015 7:21:48 AM
DiagnoCure (CUR)'s New Prostate Cancer Multimarker Urine Test Featured At A Recent Press Event Of The American Urological Association 5/21/2015 7:40:22 AM
DiagnoCure (CUR) Announces Results Of Its Annual And General Meeting Of Shareholders 5/1/2015 7:43:35 AM
Cash-Strapped DiagnoCure (CUR) Permanently Lays Off Undisclosed Number of Workers 4/24/2015 6:35:07 AM
DiagnoCure (CUR) Announces First Quarter 2015 Results 3/6/2015 6:52:35 AM
DiagnoCure (CUR) Announces Fourth Quarter 2014 And Year-End Results 1/23/2015 10:43:27 AM
12345678910...
//-->